Dave Ricks is chair and chief executive officer of Eli Lilly and Company. He joined the company 30 years ago and has held roles in business development, marketing, country management and drug development. Dave became CEO in January 2017 and was elected chair of the company’s board of directors effective June 2017.
A global biopharmaceutical leader, Lilly has been pioneering life-changing discoveries for nearly 150 years – and today the company’s medicines help more than 71 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, Lilly scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges – including diabetes, obesity, Alzheimer’s disease, cancer and debilitating autoimmune diseases. Under Dave’s leadership, Lilly has delivered record R&D output and business results, positioning the company for strong growth and expanded impact on human health around the world.
Dave joined Lilly in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving into international leadership positions. He led Lilly’s operations as general manager in Canada and China and then returned as president of Lilly USA, the company’s largest affiliate. In 2012, Dave was promoted to president of Lilly Bio-Medicines, then the company’s largest business unit, overseeing drug development and commercial operations in neuroscience, pain and immunology.
Dave earned a bachelor’s degree from Purdue University in 1990 and an MBA from Indiana University in 1996. Recently, Dave was awarded an honorary doctorate in Pharmaceutical Management from Purdue.
Dave serves on the board of directors for Adobe and Business Roundtable. In addition, he is a member of the board and former board chair of Pharmaceutical Research and Manufacturers of America. Dave is a member of the International Federation of Pharmaceutical Manufacturers & Association’s CEO Steering Committee, The Business Council and the U.S. Patent and Trademark Office’s Council for Inclusive Innovation.
Closer to home, Dave is heavily engaged in the development and well-being of Central Indiana and serves on the executive committee and board of Central Indiana Corporate Partnership.
Lucas Montarce is executive vice president and chief financial officer of Eli Lilly and Company.
Since joining Lilly in 2001, Lucas has held strategic global leadership positions in various countries in Latin America, Europe and the United States, including serving as president and general manager for the Spain, Portugal, and Greece hub. He also served as group vice president, corporate controller and chief financial officer of Lilly Research Laboratories; senior vice president, finance and chief financial officer of Lilly International; and senior vice president, finance and global chief financial officer of Elanco Health.
Born in Buenos Aires, Argentina, he holds a bachelor’s degree in business accounting from Catholic University (Argentina) and a master’s degree in business administration from the Center for Macroeconomic Studies of Argentina (CEMA).
Lucas is currently a member of the board of directors of Christel House, a global non-profit organization focused on educating and transforming the lives of underprivileged children worldwide.
Daniel M. Skovronsky, M.D., Ph.D., is chief scientific and product officer of Eli Lilly and Company and president of Lilly Research Laboratories.
In this combined role, Dan leads research and development while carrying global commercial responsibility for Lilly Cardiometabolic Health, Lilly Immunology and Lilly Neuroscience. This span reflects Lilly’s commitment to the full spectrum of medicine development, from discovery through commercialization, recognizing that innovation isn’t finished when a molecule becomes a medicine, but when people use that medicine to improve their health.
Dan also oversees Lilly’s External Innovation Team, including Catalyze360, which empowers biotech innovation through strategic capital, lab space, and R&D capabilities. He joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals, which he founded in 2004.
Dan earned his M.D. and Ph.D. from the University of Pennsylvania and a B.S. in molecular biophysics and biochemistry from Yale University.
His recognition includes being named TIME100 Most Influential in Health, the Melvin R. Goodes Prize for lifetime efforts against Alzheimer’s disease, and the 2025 Kavli Oxford Lecture Award for contributions of incretins to human health. Medicines he has helped create have been named Cleveland Clinic’s #1 Innovation of 2011 and the 2023 Prix Galien Best Pharmaceutical Product.
Andrew Adams is group vice president, Molecule Discovery, at Eli Lilly and Company.
In this role, Andrew is responsible for leading the discovery of new therapies across Lilly, spanning small molecules, antibodies, peptides and genetic medicines. Andrew also is responsible for sensory (hearing & vision) and infectious disease R&D at Lilly.
Prior to joining Lilly in 2011, Andrew was a postdoctoral fellow at Harvard Medical School. During his time at Lilly, he has served in a number of roles in discovery, external innovation and as a leader of Lilly’s discovery teams, spanning diabetes & complications, neuroscience, sensory disorders and most recently, infectious disease.
Andrew holds a degree in biology and a doctorate in zoology from the University of Aberdeen, Scotland.
Ilya Yuffa is executive vice president of Eli Lilly and Company and president of Lilly USA and Global Customer Capabilities.
Ilya served most recently as executive vice president and president of Lilly International and previously as senior vice president of Lilly Bio-Medicines and vice president of U.S. Diabetes for Lilly USA.
Since joining Lilly in 1996 as a financial analyst, Ilya has held positions in finance, business development, sales and general management. He served as managing director of Lilly Israel and in senior roles in sales and within Six Sigma and ethics and compliance. In 2017, he was named president and general manager of Lilly’s Italy Hub.
Ilya earned a Bachelor of Science degree from Tulane University and a Master of Business Administration degree from the London Business School.
Ilya is a board member of the Biotechnology Innovation Organization (BIO) and represents Lilly on the management committee of Business Equity for Indy.
Impact Obesity at Scale
Ken Custer is executive vice president of Eli Lilly and Company and president of Lilly Cardiometabolic Health.
Ken joined Lilly in 2009 and has held a wide range of roles across sales, marketing, R&D leadership, and business development. Most recently, he served as president and general manager of Lilly Canada, where he drove above-plan performance and industry-leading growth. Prior to that he was head of corporate business development, overseeing dozens of licensing and partnership deals including the acquisitions of Akouos, Prevail, and Protomer Technologies. He has also led molecule teams, including the early development of tirzepatide, and served as a principal architect for Lilly’s R&D transformation efforts that drove industry-leading speed and productivity.
Ken earned his bachelor’s degree in biochemistry and molecular biology from Reed College in 2001, a Ph.D. in neuroscience from the University of Washington in 2006, and an MBA from the Wharton School of University of Pennsylvania in 2009.
Ruth Gimeno is group vice president, Diabetes and Metabolic Research, at Eli Lilly and Company.
In this role, Ruth oversees cardiometabolic research and early clinical development. She is responsible for building Lilly’s cardiometabolic pipeline and has led the teams that advanced key approved and investigational therapies, including tirzepatide, orforglipron, retatrutide, and eloralintide for obesity and related conditions; insulin efsitora for diabetes; and lepodisiran and muvalaplin for cardiovascular disease.
Before joining Lilly in 2011, she held research leadership roles at Millennium Pharmaceuticals, Wyeth, and Pfizer.
Ruth received her medical training at Julius-Maximilians-Universität Würzburg, Germany, and her Ph.D. in biology from MIT.
Big Ideas
Adrienne Brown is executive vice president of Eli Lilly and Company and president of Lilly Immunology.
Previously, Adrienne served as group vice president and head of Corporate Business Development, overseeing all licensing, acquisition and collaboration deals from discovery through late-stage development and commercial partnerships.
Over her more than 20-year career at Eli Lilly and Company, Adrienne has held leadership roles across multiple brands and geographies, spanning business development, sales, marketing and commercial strategy. She served as group vice president of Lilly’s U.S. diabetes and obesity business unit, delivering the launch of Mounjaro.
Adrienne earned a Master of Business Administration degree from Florida Agricultural & Mechanical University.
Adrienne earned recognition as one of the top 10 Fiercest Women in Life Sciences in 2024.
Carole Ho is executive vice president of Eli Lilly and Company and president of Lilly Neuroscience.
Carole has been recognized for strategic leadership in advancing neuroscience innovation and organizational growth. With a proven ability to build and scale integrated development organizations, Carole has guided teams through the full spectrum of drug development, driving progress from early research to pivotal clinical milestones and global launches.
Before joining Lilly, Carole was the founding chief medical officer and head of development at Denali Therapeutics, where she established a dynamic development infrastructure that accelerated progress across multiple neurological indications.
Throughout her career, Carole has championed innovative approaches to clinical research, spearheaded landmark prevention trials, and cultivated partnerships that have shaped the future of neuroscience. With a foundation in neurology and biochemical sciences, she brings deep expertise and a passion for advancing patient care through bold, strategic leadership.
Carole completed her residency in neurology at Massachusetts General Hospital/Brigham and Women’s Hospital, where she also served as chief resident. She obtained her M.D. from Cornell University and S.B. in Biochemical Sciences from Harvard College.
Carole currently serves on the boards of Beam Therapeutics, Royalty Pharma and TargetALS.
Jake Van Naarden is executive vice president of Eli Lilly and Company, president of Lilly Oncology and head of Corporate Business Development.
Jake oversees all aspects of oncology spanning discovery through commercial and has responsibility for Lilly’s corporate business development function.
Jake joined Lilly in 2019 when the company acquired Loxo Oncology, Inc., where he was the chief operating officer. Following the acquisition, Jake played a key role in establishing the oncology research and development program.
In his earlier roles, Jake worked in various biotechnology investing, operational, and advisory capacities, including positions with HealthCor Management, Aisling Capital and Goldman Sachs.
Jake received his A.B. degree in molecular biology from Princeton University.
Mark Genovese is senior vice president, Immunology R&D, at Eli Lilly and Company.
In this role, Mark oversees all development endeavors in the areas of Rheumatology, Gastroenterology, Dermatology and Allergy. Prior to joining Lilly, he served as senior vice president for Clinical Development for Inflammation and Fibrosis at Gilead Sciences. Before joining industry, he was the James W. Raitt Professor of Medicine and Clinical Chief of the Division of Immunology and Rheumatology at Stanford University.
Mark led a clinical research program focused on translational medicine in autoimmune diseases. He designed and led numerous investigator-initiated studies and international multi-center trials investigating novel therapies and therapeutic strategies for the treatment of autoimmune disease. Mark is an author of over 200 peer reviewed articles, editor on the 7th edition of Kelley’s Textbook of Rheumatology. He is the 2008 recipient of the American College of Rheumatology Henry Kunkel award.
Mark received his bachelor’s degree from the University of Notre Dame, his medical degree from the Johns Hopkins University School of Medicine and completed an internship, residency, and chief residency in the Department of Medicine at Stanford University. He remained at Stanford as a fellow in the Division of Immunology and Rheumatology before joining the faculty in the same division.
Mark Mintun is group vice president, Neuroscience R&D, at Eli Lilly and Company.
In this role, Mark leads Lilly’s neuroscience research and clinical development, spanning Alzheimer’s disease, Parkinson’s disease, chronic pain, and neuropsychiatry. Under his leadership, Lilly’s Alzheimer’s program delivered Kisunla (donanemab-azbt), the first amyloid-targeting therapy with evidence supporting a limited-duration course of treatment. Kisunla was approved by the U.S. FDA in July 2024 and by the European Commission in September 2025 and is now authorized in nearly 50 countries. Mark is a co-author of the pivotal TRAILBLAZER-ALZ 2 trial (JAMA, 2023) and its three-year long-term extension, as well as the TRAILBLAZER-ALZ 6 modified-titration work that reduced ARIA risk and informed Kisunla’s updated labeling. He also oversees Lilly’s next-generation Alzheimer’s portfolio, including remternetug and secondary-prevention trials in preclinical disease, and the company’s non-opioid pain pipeline, expanded in 2025 through the acquisition of SiteOne Therapeutics.
Over the past year, Mark has led Lilly’s expansion into neuropsychiatry, launching eight Phase 2 and Phase 3 trials of brenipatide, a dual GIP/GLP-1 receptor agonist, across substance use disorders (alcohol, tobacco, and opioid use) and psychiatric conditions (recurrent major depression, bipolar disorder relapse, and schizophrenia). In 2026, Lilly further broadened its mental health portfolio with the acquisition of AtaiBeckley and its pipeline of rapid-acting neuroplastogens for treatment-resistant depression and other neuropsychiatric conditions.
Mark joined Lilly in 2010 through Avid Radiopharmaceuticals, where he led development of amyloid and tau PET imaging agents, and assumed leadership of Lilly’s Pain and Neurodegeneration R&D in 2018 and his current role in 2021. Previously, he was professor and vice-chair of Radiology at Washington University School of Medicine’s Mallinckrodt Institute of Radiology, with joint appointments in Psychiatry, Neurology, Bioengineering, and Anatomy and Neurobiology. He has authored more than 200 peer-reviewed publications.
Mark holds a B.S. in chemical engineering from MIT and an M.D. from Washington University.
Kevin Craig is vice president, Late-Phase Neuroscience, at Eli Lilly and Company.
Previously, Kevin was chief medical officer of AtaiBeckley, where he led the entirety of atai’s clinical-stage research & development effort, clinical development, patient safety, clinical operations, regulatory affairs, biostatistics, early commercial and other clinical functions. Kevin was a member of AtaiBeckley’s leadership team since 2021. He has 18 years industry experience and a decade in clinical and academic settings.
Prior to joining AtaiBeckley, he was Head of Early Clinical Development at Jazz Pharmaceuticals (formerly GW Pharmaceuticals) where he was responsible for the design and execution of rapid decision-making clinical trials across the early neuroscience pipeline. Before joining the industry, Kevin held a faculty appointment at the Behavioral and Clinical Neuroscience Institute at the University of Cambridge and has published widely on cognition and brain imaging in mental health.
Kevin received his medical degree from the University of the Witwatersrand, South Africa, and his MPhil from the University of Cambridge. He was trained in Psychiatry in Cambridge, UK and is UK board-certified in adult psychiatry and addiction medicine.
Sekar Kathiresan is senior vice president and head of Obesity Research at Eli Lilly and Company. Prior to the Lilly acquisition, he served as the chief executive officer of Verve Therapeutics.
In this role, Sekar leads the Obesity Pillar within Cardiometabolic Research and oversees a broad portfolio spanning obesity and metabolic disease as well as Verve’s pioneering gene editing programs for cardiovascular disease.
A single treatment that lowers cholesterol for life to prevent heart attack: this is the idea at the heart of Sekar’s work. A cardiologist and human geneticist, he has spent his career studying the inherited basis for heart attack and translating those insights into new medicines. His discovery of human genetic mutations that confer lifelong protection against cardiovascular disease provided the scientific foundation for Verve Therapeutics, which he founded in 2018 to replace decades of daily pills with a one-time gene editing treatment. Verve’s programs target PCSK9, ANGPTL3, and LPA to durably lower the three main lipid drivers of cardiovascular disease: LDL cholesterol, triglycerides, and lipoprotein(a). Lilly acquired Verve in July 2025.
Prior to founding Verve, Sekar served as director of the Center for Genomic Medicine at Massachusetts General Hospital, director of the Cardiovascular Disease Initiative at the Broad Institute, and professor of medicine at Harvard Medical School, where his laboratory studied the inherited basis for blood lipids and myocardial infarction.
Sekar graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. He completed clinical training in internal medicine and cardiology at MGH and postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.
For his research contributions, Sekar has been recognized by the American Heart Association with its highest scientific honor, the Distinguished Scientist Award, and by the American Society of Human Genetics with the 2018 Curt Stern Award.
John Pagelis senior vice president, Clinical Development, and global head of Hematology at Eli Lilly and Company.
In this role, John leads the development of therapies targeting biological pathways and biochemical features specific to hematologic malignancies.
John’s career has been driven by an interest in the development of novel targeted therapies for hematologic malignancies using technologies that could be translated broadly across all cancers. His research focused on the targeted delivery of radiation in lymphoma using pre-targeting technology, and the delivery of targeted immunotherapy agents for patients with hematologic malignancies. His work is deeply rooted in personal family ties to cancer and a lifelong commitment to advancing meaningful treatments for people with blood cancer, both through scientific innovation and active involvement in the important work of patient advocacy organizations.
John has held prominent academic and clinical leadership roles, including serving as Chief of Hematologic Malignancies and Director of Stem Cell Transplantation at the Swedish Cancer Institute in Seattle, WA and Professor of Medicine, Division of Oncology at the University of Washington. His research has been supported by multiple grants from the National Institutes of Health (NIH) and several career development awards from the Damon Runyon Cancer Research Foundation, the Lymphoma Research Foundation and the American Society of Clinical Oncology, leading him to author more than 200 peer-reviewed publications in leading medical journals.
John received his B.A. in Biology from the University of California, Los Angeles, his Ph.D. in Microbiology and Molecular Genetics from the University of California, Irvine, and his M.D. (magna cum laude) from Boston University School of Medicine. He completed an internal medicine residency at the University of California, San Francisco, and an oncology fellowship at the University of Washington.
Arjun Balar is senior vice president and head of Oncology Global Clinical Development at Eli Lilly and Company.
In this role, Arjun is accountable for the clinical development strategy and execution for all heme and solid tumor oncology programs at Lilly, spanning early and late phase trials and across all modalities.
Before joining Lilly, he was an Associate Professor of Medicine at the NYU Grossman School of Medicine, Director of the Genitourinary Medical Oncology Program and Medical Director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Health. At NYU Langone, he led the clinical development of several novel immunotherapies and antibody drug conjugates in localized and advanced urothelial cancers which are now global standards of care.
Arjun received his M.D. degree from the University of South Florida – Morsani College of Medicine and completed a residency in Internal Medicine at New York-Presbyterian Hospital/Weill-Cornell Medical Center and a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center.
Lillian Smyth is senior vice president, Clinical Development, and global head of Breast Cancer at Eli Lilly and Company.
In this role, Lillian leads global clinical development across Lilly’s breast cancer portfolio.
Before joining Lilly, Lillian was a Consultant Medical Oncologist and breast cancer specialist at St. Vincent’s University Hospital, Dublin, and, prior to that, an Attending Physician on the Breast Medicine and Early Drug Development services at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York.
Lillian received her medical degree (MB BCh BAO, Hons) from University College Dublin, trained in internal medicine and medical oncology with the Royal College of Physicians of Ireland (MRCPI), and completed an Advanced Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center.
